Previous studies have identified mRNA three isoforms encoding interleukin-15 (IL-15) that are produced through differential splicing and encode for the same mature IL-15 protein with two different signal peptides. Our analysis of mouse intestinal epithelial cells revealed two new IL-15 mRNA isoforms generated by different alternative splicing events. In one form (IL-15DE6), exon 6 is absent, and in the second form the first 48 nt of exon 7 are absent (IL-15DE7) through usage of an alternative 5 0 splicing site within exon 7. These mRNA isoforms encoded in-frame IL-15 protein variants lacking either 15aa (IL-15DE6) or 16aa (IL-15DE7) both utilizing the normal long signal peptide. Significant structural changes were predicted for these new IL-15 isoforms. RNAse protection assays revealed the highest expression of isoform mRNA in the intestinal epithelium and functional analysis of recombinant IL-15 isoform proteins suggested possible regulatory functions.
Introduction
Interleukin 15 (IL-15) is a 14-15 kDa glycoprotein of 114aa and belongs to the 4a-helix bundle family of cytokines (including IL-2, -4, -6, -7, -9, -15 and -21). IL-15 operates through a receptor consisting of a high-affinity IL-15 receptor a-chain, the IL-2/15 receptor b-chain and the common g-chain (gC).
1,2 IL-15 shares some biological functions with IL-2 with respect to in vitro stimulation of T-cell activation and proliferation, induction of NK-cell cytolytic activity and immunoglobulin production by B cells. [3] [4] [5] [6] Recent studies have established the pivotal role of IL-15 in the development, homeostatic proliferation and activation of NK cells, NKT cells and intestinal IELs. [7] [8] [9] [10] [11] [12] IL-15, along with IL-7, is also essential for the homeostatic regulation of CD8 memory T cells. [13] [14] [15] [16] [17] [18] At least in the case of CD8 memory T-cell proliferation and NK-cell survival, IL-15 operates through an unusual mechanism termed transpresentation in which the IL-15Ra-chain expressed by one cell type presents bound IL-15 to cells expressing the IL-15Rb and the gC. 7, 16, [19] [20] [21] Further studies reveal IL-15 as a pleiotropic cytokine with broader biological functions beyond regulation of the immune system such as mediating anabolic effects on skeletal muscle. 22, 23 As a potent immunomodulator with broad biological functions, IL-15 expression is tightly controlled at the level of transcription, translation and intracellular trafficking. 24 Alternative splicing is a common regulatory mechanism used to generate variants of many biologically and immunologically important molecules such as TCR z, IL-2, IL-4, IL-6, IL-10, CD44, and CD45, and also applies to IL-15. 25 In the cases of IL-2, IL-4 and IL-6 splice variants each lacking an exon are believed to be natural inhibitors of cytokine signaling, essentially acting as dominant negative forms of the cytokine that compete with the full-length cytokine for receptor binding. [26] [27] [28] For IL-15, the mRNA splice variants identified thus far all encode the same fulllength mature protein but with two distinct signal peptides. Alternative splicing results in generation of three IL-15 mRNA isoforms produced through the following exon usage combinations: Exons 1-2-3-4-5-6-7-8; Exons 1-3-4-5-6-7-8 or Exons 1-3-4-F (alternative exon 5)-5-6-7-8). The IL-15 isoforms utilize either the short signal peptide (sequence-specific (SSP), 21aa in human, 26aa in mouse) or an unusually long signal peptide of 48aa (LSP). 29 Although IL-15 expression is thought to be tightly controlled, it remains unclear whether tissue-specific expression and regulation of IL-15 isoforms exists. Previous research showed that both IL-15 mRNA isoforms with SSP and LSP sequences were expressed in activated monocytes/macrophages, several cell lines, testis, heart, thymus and appendix, while only the LSP-IL-15 isoform mRNA was expressed in skeletal muscle and kidney. [30] [31] [32] We have now identified two novel isoforms of IL-15 mRNA present in mouse intestinal epithelium, one lacking exon 6 and the other lacking a portion of exon 7. Both encode in-frame proteins using the LSP and appear to inhibit full-length IL-15 in mediating proliferation.
Results

Molecular cloning of new IL-15 isoforms
The mouse IL-15 gene consists of 7 introns and 8 exons, 33 while part of intron 4 was identified later as an alternative exon 5. 34 Two IL-15 mRNA isoforms with different signal peptide-coding sequences (48aa LSP and 26aa SSP) are present in a variety of mouse tissues. [30] [31] [32] 35 Since IL-15 is known to be expressed in the intestinal epithelium [36] [37] [38] we wished to determine whether tissuespecific expression of IL-15 isoforms existed in the mouse intestine. To this end, we performed reverse transcription PCR for IL-15 from mouse intestinal epithelial cell RNA. Two products of 619 and 483 bp are predicted for the isoforms associated with use of the LSP and SSP, respectively. However, three cDNA products in the 400-650 bp range were obtained (Figure 1a) . The products were cloned into a TA vector and recombinant plasmids were selected that contained one of each of the three products as shown by restriction enzyme digestion ( Figure 1b) . The isolated PCR products were then subjected to DNA sequencing which confirmed that the mid-sized product represented normal IL-15 cDNA and that the largest product corresponded to the IL-15 isoform utilizing alternative exon 5 that results in the addition of 136nt. Sequencing of cDNA derived from multiple plasmids revealed that the smallest PCR product actually contained two sequences that were either 45 or 48 nt shorter than the normal IL-15 cDNA sequence (Figure 1c ). Sequence alignments were used to compare these sequences to IL-15 cDNA. Neither sequence contained the alternative exon 5 ( Figure 1c) . In one isoform, exon 6 (45 nt) was absent with the remainder of the sequence identical to normal IL-15, we termed this isoform IL-15DE6 (GenBank accession number DQ083236); in the other isoform the first 48 nt of exon 7 were absent through usage of an alternative 5 0 splice site 5 0 CAG|GU3 0 within exon 7, and hence we termed this variant IL-15DE7 (GenBank accession number DQ083237). Thus, the two cDNA isoforms differed in length by only 3 nt which explained the inability to separate the products by standard gel electrophoresis.
Predicted protein sequence and secondary structure of IL-15DE6 and IL-15DE7 isoforms According to the inclusion or exclusion of exon 2 and alternative exon 5, previous studies had identified three alternatively spliced IL-15 mRNA isoforms (Figure 1d as derived from Nishimura et al.
29
). Despite the usage of different signal peptide coding sequences, the known isoforms encode for the same mature protein. In the new isoforms described here, the absence of exon 6 in IL-15DE6 or part of exon 7 in IL-15DE7 would result in production of distinct truncated mature proteins (Figure 1d ). This was revealed in the deduced protein sequences of IL-15DE6 and IL-15DE7 both of which encode in-frame proteins. (Figure 2a ). In addition, while the IL-15DE6 protein would retain the intrachain disulfide bond sites present in mature IL-15, the sequence changes in IL-15DE7 would result in loss of two cysteines involved in disulfide bridging ( Figure 2b) .
As IL-15 is a member of the 4a-helix bundle cytokine family, we also analyzed the secondary structure of the new IL-15 isoforms (Figure 2c ). The IL-15DE6 form contained all 4a helices (A-D), although a shorter linking loop between the A and B helices resulted from the absence of the 15aa encoded by exon 6. Interestingly, a similar structure with a shorter loop between the first 2 a helices is present in the antagonistic alternatively spliced isoforms of IL-2 and IL-4. 26, 39 Considering the similarity of structure and biological functions between IL-15 and IL-2, it is possible that IL-15DE6 could be an antagonist of normal IL-15. In the case of IL-15DE7, dramatic changes in secondary structure were predicted with the loss of the second a helix (Figure 2c ). IL-15Ra binding sites for mouse IL- 15 have not yet been identified, but the second and the third a helices of human IL-15 are interaction sites for human IL-15Ra. 40 If this holds true for mouse IL-15, IL-15DE7 may have altered binding activity for IL-15Ra or IL-15Rbg-chains.
Tissue distribution and relative abundance of IL-15 isoforms
In order to determine the tissue expression pattern of the two new isoforms as compared to normal IL-15, we designed an antisense probe of 414 nt, which could detect all three mRNA isoforms based on size differences. After separation by denaturing polyacrylamide gel electrophoresis (PAGE), all three IL-15 mRNA isoforms were detected with the normal form yielding a 288 nt protected fragment, IL-15DE7 a 240 nt fragment, and IL-15DE6 a 195 nt fragment ( Figure 3a) . The relative abundance of each isoform was also quantitated by analyzing signal intensity (Figure 3b ). mRNA for the normal form of IL-15 was present in nearly all tissues tested but was most abundant in lung, kidney, heart, and intestine ( Figure 3a and b). Both IL-15DE7 and IL-15DE6 mRNA were less abundant than mRNA for the fulllength IL-15mRNA. The highest levels of mRNA for IL-15DE7 and IL-15DE6 were present in duodenum, cecum and small intestinal epithelium. IL-15DE6 mRNA ), variant 1 and 3 encode for the long signal peptide/LSP IL-15, variant 2 encodes for the short signal peptide/SSP IL-15. The new isoforms contain the sequences encoding for the long signal peptide/LSP but DE6 lacks exon 6 and DE7 contains only a portion of exon 7. Exon 2 is shown in a box with dashed lines to indicate the assumption of its existence in the new isoforms since our PCR amplification initiated from the ATG in exon 3.
Novel IL-15 isoforms generated by alternative splicing X Tan and L Lefrançois expression was substantially greater than expression of IL-15DE7 mRNA in all tissues where expression was detected. Interestingly, while IL-15 mRNA was present in bone marrow-derived dendritic cells (DC), whether or not they were treated with LPS, isoform mRNA levels were negligible. With respect to the SSP IL-15 mRNA
Novel IL-15 isoforms generated by alternative splicing X Tan and L Lefrançois isoform containing the 136 nt of alternative exon 5, our antisense probe should protect two fragments of 109 nt and 178 nt. However, we were unable to consistently detect fragments of these sizes suggesting that this isoform is poorly expressed in the tissues analyzed. Novel IL-15 isoforms generated by alternative splicing X Tan and L Lefrançois antibody used and were B2 kDa smaller than normal IL-15 ( Figure 4a ). To determine whether the isoforms had functional activity assays using the IL-15-dependent cell line CTLL-2 were performed. His-tagged IL-15 supported dose-dependent proliferation of CTLL-2 cells, while neither His-IL-15DE7 nor His-IL-15DE6 induced CTLL-2 cell proliferation (Figure 4b ). To test if the IL-15 isoforms had an antagonistic effect on IL-15-driven CTLL-2 proliferation, a blocking assay was carried out by adding graded amounts of either recombinant His-IL-15 (as a positive control) or the variant his-tagged proteins along with a constant amount of commercially available IL-15 (Figure 4c-e) . Addition of His-IL-15 as expected resulted in an additive effect on CTLL-2 proliferation (Figure 4c ). In contrast, His-IL-15DE7 substantially blocked IL-15-mediated CTLL-2 proliferation and this effect was titratable (Figure 4d ). His-IL-15DE6 also exhibited some inhibitory effect but only at the highest concentration (Figure 4e) . Although further studies using more highly purified preparations are needed, these results suggested that similar to previously described isoforms of other cytokines, the IL-15 variants reported here may be natural antagonists of cytokine function.
Discussion
IL-15 mRNA is constitutively expressed in a variety of parenchymal tissues including placenta, skeletal muscle, kidney, heart, lung, brain, intestinal epithelium but is also expressed in hematopoietic cells of the myeloid lineage such as macrophages and DC. As IL-15 is a potent immunomodulator and has the potential for pleiotropic effects on many organ systems, expression of the cytokine is strictly regulated on multiple levels. 24 The 5 0 regulatory region of both the mouse and human IL-15 genes contains an interferon response factor element (IRF-E) and NF-kB binding site which are involved in the induced upregulation of IL-15 mRNA expression. IL-15 is predominantly regulated at the post-transcriptional level. Multiple upstream initiation codons (5 AUGs in mouse, 12 AUGs in human) on the 5 0 untranslated region (UTR) of IL-15 mRNA impede efficient protein translation. A regulatory sequence in the 3 0 UTR of IL-15 mRNA also inhibits secretion of IL-15. 41 Alternative splicing also controls IL-15 expression. Previously described IL-15 mRNA isoforms encode the same mature IL-15 protein that use different signal peptides: a LSP of 48aa produced by using the authentic initiation codon in exon 3 and the SSP (21aa in human, 26aa in mouse) resulting from a premature stop codon and use of an initiation codon in alternative exon 5. 29 These different signal peptides direct the trafficking of IL-15 to distinct intracellular compartments. The SSP isoform has high translational efficiency but is poorly secreted, while the LSP isoform is translated less efficiently but is directed into the ER-Golgi pathway and secreted. Novel IL-15 isoforms generated by alternative splicing X Tan and L Lefrançois
The functional outcomes of these regulatory events in vivo remain obscure. However, regulation of IL-15Ra is also complex with the potential existence of multiple receptor isoforms. 33, [44] [45] [46] Thus, coregulation of IL-15R and IL-15 expression may result in additional functional diversity. Indeed, the variants described here could have binding affinity for as yet uncharacterized IL-15Ra isoforms.
The discovery of novel isoforms encoding previously undescribed distinct mature IL-15 proteins indicated further complexity in the IL-15/IL-15Ra system. In general, expression of protein isoforms resulting from alternative mRNA splicing is now recognized as a common evolutionary method of generating functional diversity and developmental or tissue-specific regulation. More specifically, our finding of new IL-15 isoforms is in keeping with other 4a-helix cytokine family members that also generate variants. Both IL-2 and IL-4 have alternatively spliced isoforms with competitive inhibitory effects on cytokine function. 26, 27, 39 The long AB loop in both IL-2 and IL-4 is involved in binding to IL-2Ra, and the loss of a major portion of the AB loop encoded by exon 2 as a result of alternative splicing, generates natural antagonists termed IL-2d for IL-2 and IL-4d2 for IL-4. These variants inhibit T-cell proliferation induced by their respective full-length cytokine counterparts, 26, 27 and our data suggested a similar function for the IL-15DE7 isoform and perhaps the IL-15DE6 isoform. However, in the case of IL-15, the AB loop in hIL-15 appears not to be involved in binding of IL-15 to IL-15Ra. 40 It should also be kept in mind that IL-15Ra has high affinity for IL-15 while IL-2Ra only binds IL-2 with high affinity in the presence of IL-2/IL15Rb and gC. Furthermore, since transpresentation of IL-15 by IL-15Ra is a major mechanism of IL-15-mediated function, 2 in the absence of structural and stoichiometric data, it remains difficult to predict the precise interactions of IL-15 or IL-15 isoforms with IL-15Ra, IL2/IL15Rb and gC.
The higher levels of mRNA expression for IL-15DE6 and IL-15DE7 in the intestinal epithelium may suggest specific functions in that site. IL-15 plays an important role in development of mucosal T-cell subsets, particularly intraepithelial lymphocytes (IELs). The development of CD8aa TCRgd and TCRab IEL is IL-15 dependent 14, 47 and recent data indicate that IL-15 is an important factor in regulating rearrangement of the major TCRg V-segment expressed by IEL. 48 Moreover, IEL development or survival is mediated via transpresentation that requires expression of IL-15 and IL-15Ra by intestinal epithelial cells. 12 Thus, it remains possible that the isoforms described here could play a role in mediating important regulatory functions in the intestinal epithelium. As these isoforms contain the LSP, it would be expected that these proteins would be secreted although further studies are needed to determine their expression pattern in vivo. IL-15 can also play an apparent deleterious role in driving or exacerbating inflammation in the intestine and elsewhere, [49] [50] [51] so negative control mechanisms such as might be mediated by antagonistic IL-15 isoforms, may be needed to help dampen IL-15-mediated inflammatory events. Much further experimentation is needed to decipher the potential roles of IL-15 isoforms in normal and pathologic conditions.
Materials and methods
Mice C57BL/6J mice were purchased from the Jackson Laboratory, Bar Harbor, ME, USA.
Isolation of intestinal epithelial cells
Intestinal epithelial cells from C57BL/6J mice were isolated by a low-temperature method as previously described 52 with minor modifications. In brief, two small intestines were removed and flushed with cold Hank's balanced salt solution/0.5 mM DTT, everted onto a Pasteur pipette, cut into 2-3 mm pieces, stirred at 41C for 5 min, and pelleted by centrifugation. The intestinal pieces were then incubated in 150 ml of pH 7.3 chelating buffer (27 mM trisodium citrate, 5 mM Na 2 HPO4, 96 mM KH 2 PO4, 1.5 mM KCL, 0.5 mM dithiothreitol, 55 mM D-sorbitol, 44 mM sucrose) at 41C with constant stirring for 20 min, and then washed in 20 ml of cold chelating buffer in a 50 ml conical tube with gentle shaking. Fragments were washed with cold chelating buffer 10 times and the supernatant was collected (villus fraction). The sediment was again stirred in 100 ml fresh chelating buffer at 41C for 10 min, washed 10 times and the supernatant collected (crypt fraction). The morphology of villus cells and crypt cells was confirmed by microscopy.
Molecular cloning of IL-15 isoforms
Total RNA was extracted from intestinal epithelial cells (pooled villus and crypt fractions) using RNAeasy mini kit (Qiagen, Sciences, Valencia, CA, USA), then reversetranscribed into cDNA with oligo dT. Polymerase chain reactions were carried with primers specifically designed for mouse IL-15 coding sequences (exons [3] [4] [5] [6] [7] [8] ).
RNase protection assay
Freshly isolated tissues and organs from C57BL/6J mice were snap frozen and smashed, dissolved and homo-genized in GIT buffer (5 M guanidine isothiocyanate, 50 mM Tris-HCl pH 7.5, 10 mM EDTA pH 8.0 and 5% 2-mercaptoethanol), layered over 5.7 M CsCl then spun at 55 000 r.p.m. for 3 h. RNA quality and integrity were determined by a spectrophotometer and agarose gel analysis.
For preparation of the antisense RNA probe the following primers were used: reverse primer (735-753 nt in exon7) 5 0 caccatgctgcaattccaggagaaag 3 0 and the forward primer (466-485 nt in exons 3 and 4) 5 0 gcggcgatgaaaattttgaaaccata 3 0 . PCR products were cloned into pCR2.1-TOPO-TA vector and sequenced, then subcloned into pBlueScript II SK ( þ ) vector downstream of the T7 promoter. In vitro transcription and RPA assay was carried using RiboQuantt In Vitro Transcription kit (BD Biosciences 556850, San Diego, CA, USA) and Ribonuclease Protection Assay kit (BD Biosciences 556134) according to the manuals. In brief: the probe vector was linearized by BamHI digestion, purified and adjusted to 1 mg/ml to use as template DNA. Reaction mix included 1 ml RNasin (40 U/ml), 1 ml GTP, ATP, CTP and UTP pool (GAC: 2.75 mM each, U: 61 mM), 2 ml DTT (100 mM), 1 mg/ml probe template DNA, 10 ml [a-32 P]UTP (3000 Ci/mmol, 10 mCi/ml) and 1 ml T7 RNA polymerase (15-20 U/ml) and 4 ml 5 Â transcription buffer incubated at 371C for 1 h followed by addition of 2 ml RNase-free DNase (1 U/ ml) and digestion for 30 min at 371C, extraction in 26ul 20 mM EDTA and 2 ml yeast tRNA (2 mg/ml) with phenol: chloroform: isoamyl alcohol (25:24:1), precipitated in 4 M ammonium acetate and 100% ethanol and, washed in 90% ethanol, air dried and reconstituted in hybridization buffer. Radioactive labeling of antisense RNA probe was quantified in a liquid scintillation counter. Other probes were made similarly from probe templates of mGAPDH (BD Biosciences 556169), mL32 (BD Biosciences 556168) and mBcl-2 (Ambion, Austin, TX, USA).
The RNase protection assay was carried out as follows: 5-10 mg of RNA were hybridized with 2 ml of diluted radiolabeled probes (1 Â 10 4 c.p.m./ml) in a heat block from 90 to 561C for 16 h, cooled to room temperature, then incubated with RNase A/T1 mix (A: 80 ng/ml T1: 250 U/ml) at 301C for 45 min and treated with proteinase K (10 mg/ml) at 371C for 15 min, extracted by phenol: chloroform: isoamyl alcohol (25:24:1), precipitated in 4 M ammonium acetate and 100% ethanol at À801C for 1 h, washed in 90% ethanol, air dried and reconstituted in denaturing PAGE gel loading buffer. Probes and protected RNA samples were heated at 901C for 3 min, cooled in an ice bath, diluted to 1000-2000 c.p.m. and loaded onto a 4.75% PAGE gel. PAGE was run in 1 Â TBE buffer at 55 W constant power, then vacuum dried and exposed overnight to Kodak BIOMAX MS film under an intensifying screen at À801C. Film was developed on Kodak RP X-OMAT processor, model M7B. The dried PAGE gel containing protected radioactive 32 P-labeled RNA was exposed to a phosphor screen and an image was acquired and analyzed on a STORM860 phosphor imager. The calculation of signal intensity was based on the ratio of IL-15 RNA isoforms to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), while GAPDH signals of all samples were normalized to that of the kidney sample. Signal intensity or volume value ¼ (crude value background value) Â (kidney GAPDH value background value)/(sample GAPDH value background value).
Protein expression and purification
Recombinant pET100/D-TOPO plasmids containing mature protein-coding sequences of normal IL-15 (N), or IL-15DE6, or IL-15DE7 and positive control pET100/D-TOPO-LacZ (Invitrogen) were transformed into BL21 Start (DE3) One shot cells (Invitrogen), single colonies were picked and cultured in LB medium. N 0 terminal 6 Â His-tagged protein expression was induced by addition of 1 mM IPTG for 4-5 h, and the bacteria were harvested by centrifugation at 6000 r.p.m. for 10 min. Proteins were purified by affinity chromatography through Ni-NTA Agarose (Qiagen 30210) according to the product protocol.
Western blotting
Purified proteins were separated on 10-20% gradient SDS-PAGE (BioRad, Hercules, CA) gel and transferred onto PVDF membrane (BioRad) under constant current of 100 mA. The PVDF membrane was incubated with mouse anti-Xpress Ab (Invitrogen 46-0528), mouse antiHisG Ab (Invitrogen 46-1008) or rabbit anti-mouse IL-15 polyclonal Ab (eBiosciences, San Diego, CA, USA) followed by secondary Abs rabbit anti-mouse IgG (Sigma, St Louis, MO, USA) or goat-anti-rabbit IgG (KPL 214-1516) conjugated with HRP, and developed by ECL-advanced western detection kit (Amersham Biosciences Corp., Piscataway, NJ, USA).
CTLL-2 assay CTLL-2 cells were maintained in culture medium (Dulbecco's modified Eagle medium supplied with 10% fetal calf serum, 0.1 mM. Minimum essential medium nonessential amino acids, 2 mM L-glutamine, 5.5 Â 10 À5 M b-mercaptoethanol, 1 mM sodium pyruvate, 10 mM HEPEs pH 7.4, 50 mg/ml gentimicin sulfate, and 100 m/ ml penicillin/100 mg/ml streptomycin) with the addition of recombinant human IL-2 (obtained through the NCI BRB reagent program). For the assay, CTLL-2 cells in logphase growth were washed three times in medium without IL-2. Similar concentrations (as determined by an anti-Xpress mAb Western blot, data not shown) of purified normal IL-15, IL-15DE6, IL-15DE7 or the LacZ control recombinant protein were serially diluted in 100 ml RPMI in 96-well plates, followed by addition of 4000 CTLL-2 cells/100 ml/well. For the blocking assay, 20 ml of standard rhIL-15 80 ng/ml was added into the wells containing diluted His-N, His-IL-15DE6 or His-IL-15DE7 before the addition of CTLL-2 cells. The cells were incubated for 18 h at 371C. 1 mCi/well [ 3 H]thymidine was added into the culture for the final 6 h. Cells were harvested and [ 3 H]thymidine incorporation was measured with a liquid scintillation counter.
